Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide | Ophthalmology Times
(Image Credit: AdobeStock/Kirsten D) ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY (NCT06659445) trial evaluating xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). According to the…
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months | Ophthalmology Times
Image credit: AdobeStock/oz Interim 24-month data from a trial of the bimatoprost drug pad-IOL system (BIM-IOL system) showed sustained improvements in intraocular pressure (IOP) and visual acuity outcomes.1 The BIM-IOL system has been developed by SpyGlass Pharma, Inc. The company…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…
Evolving glaucoma therapy: A new era of interventional strategies | Ophthalmology Times
(Image Credit: AdobeStock/Yakobchuk Olena) Inder Paul Singh, MD, from The Eye Centers of Racine and Kenosha, Wisconsin, recently moderated an Ophthalmology Times Case-Based Roundtable that addressed the new playing field in glaucoma care. For Singh, the term interventional glaucoma no…
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study | Ophthalmology Times
(Image Credit: AdobeStock/Minerva Studio) Nanoscope Therapeutics has released positive 3-year follow-up data from its REMAIN study, the long-term extension of the phase 2b/3 RESTORE trial (NCT04945772) evaluating MCO-010 in retinitis pigmentosa (RP). RESTORE was a multicenter, randomized, double-masked, sham-controlled, dose-ranging study evaluating 2 dose…
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment | Ophthalmology Times
The FDA has requested additional evidence for Sydnexis’ SYD-101, a 0.01% atropine eye drop aimed at slowing myopia progression in children, despite positive outcomes from the STAR clinical trial. (Image credit: Ophthalmology Times) The FDA has sent a complete response…
AAO 2025: Margaret A. Chang, MD, MS, highlights OTX-TKI’s impact on retinal fluid | Ophthalmology Times
Margaret A. Chang, MD, MS, presented updates from the HELIOS Phase 1 trial of OTX-TKI, a sustained-release formulation of the tyrosine kinase inhibitor, axitinib, for the treatment of diabetic retinopathy (DR), at the American Academy of Ophthalmology 2025 annual meeting,…
The mechanics of presbyopia: From muscle movement to functional vision | Ophthalmology Times
(Image Credit: AdobeStock) Presbyopia-correcting eye drops share a common mechanism: They are miotic agents designed to create a smaller pupil. The power of the pupil to extend depth of focus is impressive, as observed in patients with smaller pupils who…
Starting from scratch on neovascular age-related macular degeneration | Ophthalmology Times
(Image Credit: AdobeStock) Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value of gene therapy to treat neovascular age-related macular degeneration (nAMD) at the 16th Annual Congress on Controversies…